Skip to Main Content
Table 1

Characteristics of the eGFR Study population according to quartiles of sTNFR1

Quartile 1(n = 114)Quartile 2(n = 113)Quartile 3(n = 113)Quartile 4(n = 113)Total(n = 453)P value
Baseline characteristics       
 sTNFR1 (pg/mL), range 465–1,285 1,286–1,617 1,618–2,130 2,131–11,637   
 Age, years 41 ± 13 42 ± 14 46 ± 14 52 ± 13 45 ± 14 <0.001 
 Men 46 (40) 50 (44) 36 (32) 38 (34) 170 (38) 0.18 
 Currently smoking 57 (50) 48 (42) 39 (35) 36 (32) 180 (40) 0.15 
 Diabetes* 35 (31) 41 (36) 51 (45) 67 (59) 194 (43) <0.001 
 CRP (mg/L) 5.0 (2.0, 7.6) 5.0 (3.0, 10.0) 8.0 (3.0, 14.0) 6.0 (3.8, 13.0) 6.0 (3.0, 11.0) 0.007 
 BMI (kg/m229.2 ± 6.9 30.2 ± 6.8 32.4 ± 7.0 30.9 ± 7.8 30.7 ± 7.2 0.008 
 Waist circumference (cm) 97.5 ± 15.6 100.5 ± 15.8 106.1 ± 16.0 104.9 ± 16.3 102.2 ± 16.3 <0.001 
 Blood pressure (mmHg)       
  Systolic 114 ± 16 116 ± 15 119 ± 18 123 ± 19 118 ± 17 0.002 
  Diastolic 74 ± 11 74 ± 10 76 ± 11 76 ± 10 75 ± 10 0.23 
 Antihypertensive medicine 29 (25) 34 (30) 35 (31) 70 (62) 168 (37) <0.001 
 HbA1c (mmol/mol) 47 ± 18 47 ± 18 51 ± 21 55 ± 21 50 ± 20 0.006 
 HbA1c (%) 6.5 ± 1.7 6.5 ± 1.6 6.9 ± 1.9 7.2 ± 1.9 6.8 ± 1.8 0.006 
 Total cholesterol (mmol/L) 5.1 ± 1.0 4.9 ± 1.0 4.7 ± 1.1 4.7 ± 1.1 4.8 ± 1.0 0.014 
 Statins 24 (21) 26 (23) 22 (19) 47 (42) 119 (26) <0.001 
 HDL cholesterol (mmol/L) 1.1 ± 0.4 1.1 ± 0.4 1.1 ± 0.4 1.0 ± 0.3 1.1 ± 0.3 0.63 
 Triglycerides (mmol/L) 1.7 (1.2, 2.4) 1.8 (1.2, 2.4) 1.8 (1.2, 2.5) 2.0 (1.6, 2.6) 1.8 (1.3, 2.5) 0.079 
 Albumin-to-creatinine ratio (mg/mmol) 1.2 (0.6, 2.4) 1.4 (0.7, 3.9) 1.1 (0.6, 6.2) 28.1 (2.7, 140.1) 1.7 (0.7, 13.8) <0.001 
 CKD-EPI eGFR (mL/min/1.73 m2) 104.7 ± 18.6 103.1 ± 17.0 97.6 ± 20.3 71.1 ± 31.3 94.1 ± 26.2 <0.001 
Follow-up characteristics       
 eGFR decline over follow-up (mL/min/1.73 m2/year) −2.53 ± 5.22 −1.99 ± 3.79 −2.28 ± 7.48 −5.12 ± 5.82 2.50 ± 1.12 <0.001 
 Combined renal outcome 4 (3.5) 1 (0.9) 4 (3.5) 34 (30) 43 (9.5) <0.001 
Quartile 1(n = 114)Quartile 2(n = 113)Quartile 3(n = 113)Quartile 4(n = 113)Total(n = 453)P value
Baseline characteristics       
 sTNFR1 (pg/mL), range 465–1,285 1,286–1,617 1,618–2,130 2,131–11,637   
 Age, years 41 ± 13 42 ± 14 46 ± 14 52 ± 13 45 ± 14 <0.001 
 Men 46 (40) 50 (44) 36 (32) 38 (34) 170 (38) 0.18 
 Currently smoking 57 (50) 48 (42) 39 (35) 36 (32) 180 (40) 0.15 
 Diabetes* 35 (31) 41 (36) 51 (45) 67 (59) 194 (43) <0.001 
 CRP (mg/L) 5.0 (2.0, 7.6) 5.0 (3.0, 10.0) 8.0 (3.0, 14.0) 6.0 (3.8, 13.0) 6.0 (3.0, 11.0) 0.007 
 BMI (kg/m229.2 ± 6.9 30.2 ± 6.8 32.4 ± 7.0 30.9 ± 7.8 30.7 ± 7.2 0.008 
 Waist circumference (cm) 97.5 ± 15.6 100.5 ± 15.8 106.1 ± 16.0 104.9 ± 16.3 102.2 ± 16.3 <0.001 
 Blood pressure (mmHg)       
  Systolic 114 ± 16 116 ± 15 119 ± 18 123 ± 19 118 ± 17 0.002 
  Diastolic 74 ± 11 74 ± 10 76 ± 11 76 ± 10 75 ± 10 0.23 
 Antihypertensive medicine 29 (25) 34 (30) 35 (31) 70 (62) 168 (37) <0.001 
 HbA1c (mmol/mol) 47 ± 18 47 ± 18 51 ± 21 55 ± 21 50 ± 20 0.006 
 HbA1c (%) 6.5 ± 1.7 6.5 ± 1.6 6.9 ± 1.9 7.2 ± 1.9 6.8 ± 1.8 0.006 
 Total cholesterol (mmol/L) 5.1 ± 1.0 4.9 ± 1.0 4.7 ± 1.1 4.7 ± 1.1 4.8 ± 1.0 0.014 
 Statins 24 (21) 26 (23) 22 (19) 47 (42) 119 (26) <0.001 
 HDL cholesterol (mmol/L) 1.1 ± 0.4 1.1 ± 0.4 1.1 ± 0.4 1.0 ± 0.3 1.1 ± 0.3 0.63 
 Triglycerides (mmol/L) 1.7 (1.2, 2.4) 1.8 (1.2, 2.4) 1.8 (1.2, 2.5) 2.0 (1.6, 2.6) 1.8 (1.3, 2.5) 0.079 
 Albumin-to-creatinine ratio (mg/mmol) 1.2 (0.6, 2.4) 1.4 (0.7, 3.9) 1.1 (0.6, 6.2) 28.1 (2.7, 140.1) 1.7 (0.7, 13.8) <0.001 
 CKD-EPI eGFR (mL/min/1.73 m2) 104.7 ± 18.6 103.1 ± 17.0 97.6 ± 20.3 71.1 ± 31.3 94.1 ± 26.2 <0.001 
Follow-up characteristics       
 eGFR decline over follow-up (mL/min/1.73 m2/year) −2.53 ± 5.22 −1.99 ± 3.79 −2.28 ± 7.48 −5.12 ± 5.82 2.50 ± 1.12 <0.001 
 Combined renal outcome 4 (3.5) 1 (0.9) 4 (3.5) 34 (30) 43 (9.5) <0.001 

Data are number (percentage), mean ± SD, or median (25th, 75th percentile), unless otherwise indicated.

*Diabetes was defined as HbA1c ≥48 mmol/mol (≥6.5%) or physician diagnosis of diabetes.

†CKD-EPI eGFR was calculated using the CKD-EPI eGFR equation based on serum creatinine without a correction for African American ethnicity.

‡Combined renal outcome was defined as the first of the following: an absolute 30% decline in eGFR with a follow-up eGFR <60 mL/min/1.73 m2, death from renal causes, or initiation of renal replacement therapy.

Close Modal

or Create an Account

Close Modal
Close Modal